Synergistic cytotoxicity of bentonite–zeolite 4A nanocomposite in human melanoma cells

Read full text
Authors: Nilay Duman, Atilla Evcin, Sefa Çelik, Göktürk Oraloğlu, Ayşe Caner
Cited by: 0
References: 29

Abstract

INTRODUCTION: The cytotoxic effects of bentonite and zeolite 4A nanoparticles (NPs), as well as their nanocomposite (NC), were investigated in human melanoma (G361) cells. Although both materials have demonstrated anticancer potential, their effects on melanoma remain insufficiently explored. This study aimed to evaluate the cellular responses induced by bentonite and zeolite 4A NPs, individually and in combination, in G361 cells. METHODS: Physicochemical characterization was performed using X-ray diffraction (XRD), X-ray fluorescence (XRF), and scanning electron microscopy (SEM). IC₅。 values were determined for bentonite NPs, zeolite 4A NPs, and the NC. Cell viability was assessed using the MTT assay, while apoptosis was evaluated through caspase-3 activity measured by ELISA. RESULTS: All treatments exhibited dose-dependent cytotoxicity in melanoma cells. Notably, the NC demonstrated a strong synergistic interaction, enhancing cytotoxic effects and enabling reduced effective concentrations. Despite the pronounced cytotoxicity observed in the NC group, no significant increase in caspase-3 activity was detected compared to control. These findings suggest the involvement of caspase-independent cell death mechanisms, particularly necrotic or non-classical apoptotic processes. CONCLUSION: The bentonite/zeolite 4A nanocomposite exerts synergistic cytotoxic effects in melanoma cells. While the results highlight its therapeutic potential, further mechanistic studies are required to clarify the underlying pathways prior to clinical translation.

Fields of Study & Subjects

Nanoparticles: synthesis and applications Clay minerals and soil interactions Nanoplatforms for cancer theranostics

Publication details

Journal / source
Cutaneous and Ocular Toxicology
Volume
45
Issue
2
Pages
201–207
Publication date
27 February 2026
Language
EN